Clinical Analysis of Preoperative Neoadjuvant Chemotherapy by Thalidomide Combined with Gefitinib for Non-small Cell Lung Cancer

Xu Xiao Hong

Volume 37 Issue 01

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2016 > 37(01):

Xu Xiao Hong . Clinical Analysis of Preoperative Neoadjuvant Chemotherapy by Thalidomide Combined with Gefitinib for Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University, 2016, 37(01).

Citation:

Xu Xiao Hong . Clinical Analysis of Preoperative Neoadjuvant Chemotherapy by Thalidomide Combined with Gefitinib for Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University, 2016, 37(01).

Citation:

PDF( 569 KB)

Clinical Analysis of Preoperative Neoadjuvant Chemotherapy by Thalidomide Combined with Gefitinib for Non-small Cell Lung Cancer

Xu Xiao Hong

(1)Dept. of Pneumology,Pepole’s Hospital of Hanchuan City/ Hanchuan Hospital of Pepole’s Hospital Affiliated to Wuhan University,Hanchuan Wuhan 431600;2)Dept. of Pharmacy,Fujian Provincial Hospital,Fuzhou Fujian 350001,China)

Abstract

Abstract

［Abstract］Objective To investigate the clinical effect of preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib for non-small cell lung cancer （NSCLC） patients and provide clinical basis for NSCLC therapy. Methods　From 2011/1 to 2013/1，we collected 160 NSCLC cases in our hospital and divided them into 2 groups randomly，80 cases in control group and 80 cases in observation group. The patients in the control group were treated with conventional surgical treatment and patients in the observation group were treated with preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib before surgery. The clinical effects, the 6 months and 1 year survival rates，and the toxicity effects were observed, and the clinical effects and survival rates between the 2 groups were compared. Results　The observation group had a therapeutic efficiency ratio（TER） of 80.0% which was significantly higher than the control group（50.0%），and the difference was statistically significant（P＜0.05）. The 6 months survival rate and 1 year survival rate were 97.5% and 92.5%, which were both significantly higher than those of control group（87.5% and 77.5%），and all differences were statistically significant（P＜0.05）. The toxicity effects of observation group were lower. Conclusions　Preoperative neoadjuvant chemotherapy by thalidomide combined with gefitinib for NSCLC therapy is effective and safe，which is worthy of study and further application in clinical treatment..
- ［Key words］Thalidomide；Gefitinib；Neoadjuvant chemotherapy；NSCLC,

FullText(HTML)

References(0)

References

Relative Articles(20)

Relative Articles

[1]	Shengxi YANG, Jiade ZHU, Qiurui LI, Wenlian TU. Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Journal of Kunming Medical University, 2025, 46(5): 1-7.
[2]	Ling MA, Yanhong ZHAO, Jia LIU, Wenlian TU. Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib as Second-Line Treatment of Chronic Myeloid Leukemia. Journal of Kunming Medical University, 2024, 45(4): 92-98. doi: 10.12259/j.issn.2095-610X.S20240413
[3]	Zheng ZHANG, Yanhong YANG, Zaihui FENG, Lujiang ZHAN, Jinxian PU, Qianting DUAN. Value of High Field Tntensity MRIT1 Perfusion Imaging Combined with DWI Imaging in Evaluating The Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Journal of Kunming Medical University, 2024, 45(7): 148-153. doi: 10.12259/j.issn.2095-610X.S20240722
[4]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan , Li Rui Zhi . . Journal of Kunming Medical University, 2019, 40(07): 111-115.
[5]	Zhang Zhi Xian , Gu Hou , Lin 劼, Lei Xue Fen , Jiang Li Feng , Li Nan , Lu Xin Yan , Li Ting Ting . . Journal of Kunming Medical University, 2018, 39(12): 65-68.
[6]	Yang Lin Lin . Comparative Study of Concurrent Chemoradiotherapy with Simplex Radiotherapy after Radical Surgery for High-risk Endometrial Cancer. Journal of Kunming Medical University,
[7]	Li Zhuo Lin . Assessment of Locally Advanced Breast Cancer Response to Neoadjuvant Chemotherapy with Diffusion weighted MRI. Journal of Kunming Medical University,
[8]	Zhu Tian Bo . Clinical Application of Preoperative New Adjuvant Chemotherapy in Treatment of Cervical Cancer. Journal of Kunming Medical University,
[9]	Long Xiang Yu . . Journal of Kunming Medical University,
[10]	Shang Xue Qin . . Journal of Kunming Medical University,
[11]	Zhang Ming . . Journal of Kunming Medical University,
[12]	Wu Xue Song . . Journal of Kunming Medical University,
[13]	Wang Hua . . Journal of Kunming Medical University,
[14]	Wang Jian Kui . . Journal of Kunming Medical University,
[15]	Yang Jing . . Journal of Kunming Medical University,
[16]	Yang Jie . Comparison of S-1 Combined with Radical Radiation Therapy and Single Radical Radiation Therapy in Treatment of Early Nasopharyngeal Carcinoma. Journal of Kunming Medical University,
[17]	Yang Jie . Clinical Application of I125-seed Implantation Combined with Gimeracil and Oteracil Capsules Adjuvant Chemotherapy in the Treatment of Head and Neck Cancer. Journal of Kunming Medical University,
[18]	Wu Zhi Yong . . Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	Tan Jing . . Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(21)

1.	林洪盛，刘利敏，鲁秋香，吴清. 新辅助化疗对非小细胞肺癌患者肿瘤标志物与细胞凋亡相关因子的影响. 中国医学创新. 2023(03): 45-49 .
2.	何佳，白美玲. 吉非替尼靶向治疗非小细胞肺癌对患者血清CA125、CEA、NSE水平及不良反应的影响. 当代医学. 2021(18): 167-168 .
3.	何显阳，刘方文，黄云英，赖红宇，王志春. 多西他赛联合顺铂新辅助化疗对非小细胞肺癌治疗中相关肿瘤标记物的影响. 医学信息. 2021(23): 165-167 .
4.	吴皓，李萍. 奥希替尼联合放化疗治疗晚期非小细胞肺癌患者的临床疗效及安全性分析. 中国肿瘤临床与康复. 2020(04): 400-403 .
5.	雒润华. 健脾化痰逐淤方结合靶向药物治疗晚期EGFR突变阳性肺腺癌. 深圳中西医结合杂志. 2020(14): 45-46 .
6.	章伟. 吉非替尼靶向治疗对非小细胞肺癌患者血清CA125 CEA NSE水平的影响. 基层医学论坛. 2020(26): 3846-3847 .
7.	曹参，李靖，吴勤研. 吉非替尼联合化疗方案应用于晚期肺腺癌患者的临床疗效及安全性分析. 中华肺部疾病杂志(电子版). 2020(04): 484-487 .
8.	姚丽鸽，王留晏，周寒丽，段方方，陈露，张克克. 沙利度胺联合GP方案化疗对晚期非小细胞肺癌患者生存时间和生存质量的影响. 癌症进展. 2019(12): 1400-1403 .
9.	张治业. 沙利度胺联合TP方案化疗对晚期非小细胞肺癌患者血清肿瘤标志物的影响. 淮海医药. 2019(04): 338-340 .
10.	廖丽军，李鹏辉. 新辅助化疗治疗Ⅲ期非小细胞肺癌的临床疗效观察. 中国现代医生. 2019(19): 102-104 .
11.	文慧，彭彦才，艾葆春，郝光军，李小峰. 阿帕替尼联合紫杉醇对非小细胞肺癌患者的疗效及血清因子的影响. 药物评价研究. 2019(09): 1810-1813 .
12.	莫遗盛，周伯庭，毛艳，王冬梅. 沙利度胺治疗实体瘤的研究进展. 微创医学. 2018(03): 344-347 .
13.	惠广盈，刘楠. 手术前后联合化疗对非小细胞肺癌患者生存质量及不良反应的影响. 西北国防医学杂志. 2018(01): 35-38 .
14.	顾晶晶. 吉非替尼联合沙利度胺治疗非小细胞肺癌的临床疗效分析. 中国现代应用药学. 2018(07): 1073-1076 .
15.	梁华，李彦磊，高炜. 吉非替尼联合化疗治疗原发性ⅢB、Ⅳ期非小细胞肺癌的临床研究. 中国医学前沿杂志(电子版). 2018(03): 58-61 .
16.	王宏，夏永寿，加静，张燕，王瑛. 沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果观察. 现代生物医学进展. 2018(23): 4474-4477 .
17.	武乐，叶华姝，刘震天. 吉非替尼与沙利度胺联用对非小细胞肺癌患者的临床疗效及其对CEA和CA125水平的影响. 抗感染药学. 2018(12): 2118-2121 .
18.	杨建刚，陈继正，赵参军，王昕洁，钱仲，郑瑾. 沙利度胺在治疗晚期实体肿瘤中的应用及研究进展. 现代肿瘤医学. 2017(11): 1805-1809 .
19.	玛依拉·阿不都克力木，库尔班江·吐尔逊. 沙利度胺联合吉非替尼新辅助化疗对非小细胞肺癌患者的疗效与安全性分析. 实用癌症杂志. 2017(04): 582-585 .
20.	龚玉芳，刘峰，杨志胤，姜斌. 新辅助化疗前后非小细胞肺癌患者血清CA125、CEA及CYFRA21-1的变化及预后分析. 中国医药导报. 2017(11): 91-94 .
21.	胡洪林. 吉非替尼联合简化调强放疗技术治疗非小细胞肺癌临床研究. 中国药业. 2017(09): 38-40 .